Gareth John Morgan

Genomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones

This study uses SCID-rab PDX models to analyze genomic and transcriptomic features of multiple myeloma, revealing selection of pre-existing high-risk clones.

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma

This study analyzes whole-genome sequencing data from multiple myeloma patients to show that the timing of genetic events, not just their presence, affects clinical outcomes.

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma

This paper develops a monobody-drug conjugate targeting mutant RAS in multiple myeloma, showing improved anti-tumor effects and safety in vitro and in vivo.

Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.

Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers

The paper identifies H3K4me3 broad domains formed by super-enhancer translocations in B-cell and T-cell malignancies, linking them to oncogene activation.

Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma

This study shows copy number signatures predict chromothripsis in multiple myeloma and link to poor clinical outcomes using whole genome and exome sequencing data.

Revealing the impact of recurrent and rare structural variants in multiple myeloma

This study identifies 100 SV hotspots and 31 new candidate driver genes in multiple myeloma, revealing that 63% of SVs remain unexplained and are associated with outlier gene expression.